ArticleCell death & disease2016
Non-amyloidogenic effects of α2 adrenergic agonists: implications for brimonidine-mediated neuroprotection.
Article in Cell death & disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 68 citations in OpenAlex.
- Brimonidine Therapy for Protection From Noise-Induced Hearing Loss.Aging cell · 2026Article
- Dexmedetomidine as a potential neuroprotective agent against Alzheimer's disease: molecular mechanisms and therapeutic perspectives.Frontiers in aging neuroscience · 2026Review
- Effects of taurine, brimonidine and betaxolol on oscillation modulation and stimulation efficiency in degenerated rd10 mouse retinas.Scientific reports · 2025Article
- Associations between dementia and exposure to topical glaucoma medications.Journal of Alzheimer's disease : JAD · 2025Article
- Deciphering the Role of Adrenergic Receptors in Alzheimer's Disease: Paving the Way for Innovative Therapies.Biomolecules · 2025Review
- Mapping key trends, relationships, and molecular pathways for neuroprotection in glaucoma: a bibliometric approach.International journal of ophthalmology · 2025Article
- Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review: Neuroprotective Nanocarriers in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The alpha2-adrenergic receptor agonist clonidine protects against cerebral ischemia/reperfusion induced neuronal apoptosis in rats.Metabolic brain disease · 2024Article
- Article
- Real-Time Imaging of Single Retinal Cell Apoptosis in a Non-Human Primate Ocular Hypertension Model.Translational vision science & technology · 2024Article
- A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model.PloS one · 2024Article
- Novel long-acting brimonidine tartrate loaded-PCL/PVP nanofibers for versatile biomedical applications: fabrication, characterization and antimicrobial evaluation.RSC advances · 2023Article
- Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance.Journal of personalized medicine · 2022Review
- Topical Brimonidine Delays Ultraviolet Radiation-Induced Squamous Cell Carcinoma in Hairless Mice.Photochemistry and photobiology · 2022Article
- Tools and Biomarkers for the Study of Retinal Ganglion Cell Degeneration.International journal of molecular sciences · 2022Review
- Neuronal Dysfunction Is Linked to the Famine-Associated Risk of Proliferative Retinopathy in Patients With Type 2 Diabetes.Frontiers in neuroscience · 2022Article
- Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury.Journal of nanobiotechnology · 2021Article
- Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments.Pharmaceutics · 2021Review
- Role of Retinal Amyloid-β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The amyloid beta (Aβ) pathway is strongly implicated in neurodegenerative conditions such as Alzheimer's disease and more recently, glaucoma. Here, we identify the α2 adrenergic receptor agonists (α2ARA) used to lower intraocular pressure can prevent retinal ganglion cell (RGC) death via the non-amyloidogenic Aβ-pathway. Neuroprotective effects were confirmed in vivo and in vitro in different glaucoma-related models using α2ARAs brimonidine (BMD), clonidine (Clo) and dexmedetomidine. α2ARA treatment significantly reduced RGC apoptosis in experimental-glaucoma models by 97.7% and 92.8% (BMD, P<0.01) and 98% and 92.3% (Clo, P<0.01)) at 3 and 8 weeks, respectively. A reduction was seen in an experimental Aβ-induced neurotoxicity model (67% BMD and 88.6% Clo, both P<0.01, respectively), and in vitro, where α2ARAs significantly (P<0.05) prevented cell death, under both hypoxic (CoCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.